Biotage Expands Analytical Testing Expertise with DPX Technologies Acquisition

Biotage, a renowned global supplier in drug discovery and analytical testing, has announced its acquisition of DPX Technologies, a leader in pipette tip technology, effective December 31, 2025. This acquisition will bolster Biotage’s presence in the sample preparation sector, enhancing its pipette tip technology capabilities and broadening its offerings in high-growth segments.

Biotage, well-known for its solutions in drug development and analytical testing, aims to strengthen its market leadership with the strategic acquisition of DPX Technologies. Based in Columbia, SC, DPX specialises in innovative pipette tip technology, catering to industries like clinical, forensic, genomics, proteomics, and food safety. With this acquisition, Biotage integrates DPX’s dispersive extraction technology, aligning with its existing offerings and providing a more comprehensive solution portfolio. Frederic Vanderhaegen, CEO of Biotage, expressed enthusiasm for the cultural and strategic alignment between the two companies, expecting this collaboration to accelerate growth and deliver greater customer value.

DPX Technologies, with its 45 employees, will continue its operations under current management during a smooth integration phase. Customers and partners should experience minimal disruptions in their interactions. Dr. William Brewer, DPX’s CEO, lauds the merger, emphasising the synergy between Biotage and DPX’s products, poised to enhance outcomes in drug discovery and clinical diagnoses. This acquisition marks a significant milestone in Biotage’s pursuit of leadership in sample preparation technology, ultimately aiming to improve public health outcomes through faster and more efficient analytical processes.